The viral safety of intravenous immunoglobulin
Human immunoglobulin for intravenous (IV) use has an established safety record with regard to transmission of hepatitis B virus. The bulk of available evidence also suggests that the human immunodeficiency virus (HIV) is not transmitted by IV immunoglobulin. There has been one report, however, of is...
Gespeichert in:
| Veröffentlicht in: | The Journal of infection 1987-09, Vol.15 (2), p.125-133 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 133 |
|---|---|
| container_issue | 2 |
| container_start_page | 125 |
| container_title | The Journal of infection |
| container_volume | 15 |
| creator | Cuthbertson, B. Perry, R.J. Foster, P.R. Reid, K.G. Crawford, R.J. Yap, P.L. |
| description | Human immunoglobulin for intravenous (IV) use has an established safety record with regard to transmission of hepatitis B virus. The bulk of available evidence also suggests that the human immunodeficiency virus (HIV) is not transmitted by IV immunoglobulin. There has been one report, however, of isolation of HIV from two patients with hypogammglobulinaemia who had been treated with several immunoglobulin products. Certain IV immunoglobulin products have transmitted non-A, non-B (NANB) hepatitis but careful clinical assessment of recipients of other products suggests that non-infective preparations can be made. Interpretation of available data most likely to be correct is that contamination with NANB is reduced but not eliminated by cold-ethanol fractionation and that the use of further virucidal procedures in the finishing of immunoglobulin products will confer a higher degree of safety. |
| doi_str_mv | 10.1016/S0163-4453(87)93096-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_81076269</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0163445387930969</els_id><sourcerecordid>81076269</sourcerecordid><originalsourceid>FETCH-LOGICAL-c389t-efd1948cb0b330e9e6e6a6a21886bcceb057896a302d7a22b08752c0c5610dba3</originalsourceid><addsrcrecordid>eNqFkMlOwzAQhi0EKqXwCJVyQAgOKV4SLyeEKjapEgfK2XKcCRhlKXZSqW-Pu6hXLjOH-Wbm14fQlOAZwYTff8TC0izL2a0Ud4phxVN1gsYkZzSlIqOnaHxEztFFCD8YY8UUH6ERI0RIxcZotvyGZO28qZNgKug3SVclru29WUPbDSFxTTO03VfdFUPt2kt0Vpk6wNWhT9Dn89Ny_pou3l_e5o-L1DKp-hSqkqhM2gIXjGFQwIEbbiiRkhfWQoHz-J4bhmkpDKUFliKnFtucE1wWhk3Qzf7uyne_A4ReNy5YqGvTQkylJcGCU64imO9B67sQPFR65V1j_EYTrLee9M6T3krQUuidJ73dmx4eDEUD5XHrICbOrw9zE6ypK29a68IREyLeYzJiD3sMooy1A6-DddBaKJ0H2-uyc_8E-QMLRIO1</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>81076269</pqid></control><display><type>article</type><title>The viral safety of intravenous immunoglobulin</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Cuthbertson, B. ; Perry, R.J. ; Foster, P.R. ; Reid, K.G. ; Crawford, R.J. ; Yap, P.L.</creator><creatorcontrib>Cuthbertson, B. ; Perry, R.J. ; Foster, P.R. ; Reid, K.G. ; Crawford, R.J. ; Yap, P.L.</creatorcontrib><description>Human immunoglobulin for intravenous (IV) use has an established safety record with regard to transmission of hepatitis B virus. The bulk of available evidence also suggests that the human immunodeficiency virus (HIV) is not transmitted by IV immunoglobulin. There has been one report, however, of isolation of HIV from two patients with hypogammglobulinaemia who had been treated with several immunoglobulin products. Certain IV immunoglobulin products have transmitted non-A, non-B (NANB) hepatitis but careful clinical assessment of recipients of other products suggests that non-infective preparations can be made. Interpretation of available data most likely to be correct is that contamination with NANB is reduced but not eliminated by cold-ethanol fractionation and that the use of further virucidal procedures in the finishing of immunoglobulin products will confer a higher degree of safety.</description><identifier>ISSN: 0163-4453</identifier><identifier>EISSN: 1532-2742</identifier><identifier>DOI: 10.1016/S0163-4453(87)93096-9</identifier><identifier>PMID: 3117893</identifier><identifier>CODEN: JINFD2</identifier><language>eng</language><publisher>Kidlington: Elsevier Ltd</publisher><subject>AIDS/HIV ; Animals ; Biological and medical sciences ; Hepatitis C - transmission ; Humans ; Immunoglobulin G - administration & dosage ; Immunoglobulin G - adverse effects ; Immunoglobulin G - standards ; Immunoglobulins, Intravenous ; Immunopathology ; Immunotherapy (general aspects) ; Infusions, Intravenous ; Medical sciences ; Virus Diseases - transmission</subject><ispartof>The Journal of infection, 1987-09, Vol.15 (2), p.125-133</ispartof><rights>1987 The British Society for the Study of infection</rights><rights>1988 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c389t-efd1948cb0b330e9e6e6a6a21886bcceb057896a302d7a22b08752c0c5610dba3</citedby><cites>FETCH-LOGICAL-c389t-efd1948cb0b330e9e6e6a6a21886bcceb057896a302d7a22b08752c0c5610dba3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0163-4453(87)93096-9$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=7745338$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3117893$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cuthbertson, B.</creatorcontrib><creatorcontrib>Perry, R.J.</creatorcontrib><creatorcontrib>Foster, P.R.</creatorcontrib><creatorcontrib>Reid, K.G.</creatorcontrib><creatorcontrib>Crawford, R.J.</creatorcontrib><creatorcontrib>Yap, P.L.</creatorcontrib><title>The viral safety of intravenous immunoglobulin</title><title>The Journal of infection</title><addtitle>J Infect</addtitle><description>Human immunoglobulin for intravenous (IV) use has an established safety record with regard to transmission of hepatitis B virus. The bulk of available evidence also suggests that the human immunodeficiency virus (HIV) is not transmitted by IV immunoglobulin. There has been one report, however, of isolation of HIV from two patients with hypogammglobulinaemia who had been treated with several immunoglobulin products. Certain IV immunoglobulin products have transmitted non-A, non-B (NANB) hepatitis but careful clinical assessment of recipients of other products suggests that non-infective preparations can be made. Interpretation of available data most likely to be correct is that contamination with NANB is reduced but not eliminated by cold-ethanol fractionation and that the use of further virucidal procedures in the finishing of immunoglobulin products will confer a higher degree of safety.</description><subject>AIDS/HIV</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Hepatitis C - transmission</subject><subject>Humans</subject><subject>Immunoglobulin G - administration & dosage</subject><subject>Immunoglobulin G - adverse effects</subject><subject>Immunoglobulin G - standards</subject><subject>Immunoglobulins, Intravenous</subject><subject>Immunopathology</subject><subject>Immunotherapy (general aspects)</subject><subject>Infusions, Intravenous</subject><subject>Medical sciences</subject><subject>Virus Diseases - transmission</subject><issn>0163-4453</issn><issn>1532-2742</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1987</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMlOwzAQhi0EKqXwCJVyQAgOKV4SLyeEKjapEgfK2XKcCRhlKXZSqW-Pu6hXLjOH-Wbm14fQlOAZwYTff8TC0izL2a0Ud4phxVN1gsYkZzSlIqOnaHxEztFFCD8YY8UUH6ERI0RIxcZotvyGZO28qZNgKug3SVclru29WUPbDSFxTTO03VfdFUPt2kt0Vpk6wNWhT9Dn89Ny_pou3l_e5o-L1DKp-hSqkqhM2gIXjGFQwIEbbiiRkhfWQoHz-J4bhmkpDKUFliKnFtucE1wWhk3Qzf7uyne_A4ReNy5YqGvTQkylJcGCU64imO9B67sQPFR65V1j_EYTrLee9M6T3krQUuidJ73dmx4eDEUD5XHrICbOrw9zE6ypK29a68IREyLeYzJiD3sMooy1A6-DddBaKJ0H2-uyc_8E-QMLRIO1</recordid><startdate>19870901</startdate><enddate>19870901</enddate><creator>Cuthbertson, B.</creator><creator>Perry, R.J.</creator><creator>Foster, P.R.</creator><creator>Reid, K.G.</creator><creator>Crawford, R.J.</creator><creator>Yap, P.L.</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19870901</creationdate><title>The viral safety of intravenous immunoglobulin</title><author>Cuthbertson, B. ; Perry, R.J. ; Foster, P.R. ; Reid, K.G. ; Crawford, R.J. ; Yap, P.L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c389t-efd1948cb0b330e9e6e6a6a21886bcceb057896a302d7a22b08752c0c5610dba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1987</creationdate><topic>AIDS/HIV</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Hepatitis C - transmission</topic><topic>Humans</topic><topic>Immunoglobulin G - administration & dosage</topic><topic>Immunoglobulin G - adverse effects</topic><topic>Immunoglobulin G - standards</topic><topic>Immunoglobulins, Intravenous</topic><topic>Immunopathology</topic><topic>Immunotherapy (general aspects)</topic><topic>Infusions, Intravenous</topic><topic>Medical sciences</topic><topic>Virus Diseases - transmission</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cuthbertson, B.</creatorcontrib><creatorcontrib>Perry, R.J.</creatorcontrib><creatorcontrib>Foster, P.R.</creatorcontrib><creatorcontrib>Reid, K.G.</creatorcontrib><creatorcontrib>Crawford, R.J.</creatorcontrib><creatorcontrib>Yap, P.L.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of infection</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cuthbertson, B.</au><au>Perry, R.J.</au><au>Foster, P.R.</au><au>Reid, K.G.</au><au>Crawford, R.J.</au><au>Yap, P.L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The viral safety of intravenous immunoglobulin</atitle><jtitle>The Journal of infection</jtitle><addtitle>J Infect</addtitle><date>1987-09-01</date><risdate>1987</risdate><volume>15</volume><issue>2</issue><spage>125</spage><epage>133</epage><pages>125-133</pages><issn>0163-4453</issn><eissn>1532-2742</eissn><coden>JINFD2</coden><abstract>Human immunoglobulin for intravenous (IV) use has an established safety record with regard to transmission of hepatitis B virus. The bulk of available evidence also suggests that the human immunodeficiency virus (HIV) is not transmitted by IV immunoglobulin. There has been one report, however, of isolation of HIV from two patients with hypogammglobulinaemia who had been treated with several immunoglobulin products. Certain IV immunoglobulin products have transmitted non-A, non-B (NANB) hepatitis but careful clinical assessment of recipients of other products suggests that non-infective preparations can be made. Interpretation of available data most likely to be correct is that contamination with NANB is reduced but not eliminated by cold-ethanol fractionation and that the use of further virucidal procedures in the finishing of immunoglobulin products will confer a higher degree of safety.</abstract><cop>Kidlington</cop><pub>Elsevier Ltd</pub><pmid>3117893</pmid><doi>10.1016/S0163-4453(87)93096-9</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0163-4453 |
| ispartof | The Journal of infection, 1987-09, Vol.15 (2), p.125-133 |
| issn | 0163-4453 1532-2742 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_81076269 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | AIDS/HIV Animals Biological and medical sciences Hepatitis C - transmission Humans Immunoglobulin G - administration & dosage Immunoglobulin G - adverse effects Immunoglobulin G - standards Immunoglobulins, Intravenous Immunopathology Immunotherapy (general aspects) Infusions, Intravenous Medical sciences Virus Diseases - transmission |
| title | The viral safety of intravenous immunoglobulin |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T09%3A03%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20viral%20safety%20of%20intravenous%20immunoglobulin&rft.jtitle=The%20Journal%20of%20infection&rft.au=Cuthbertson,%20B.&rft.date=1987-09-01&rft.volume=15&rft.issue=2&rft.spage=125&rft.epage=133&rft.pages=125-133&rft.issn=0163-4453&rft.eissn=1532-2742&rft.coden=JINFD2&rft_id=info:doi/10.1016/S0163-4453(87)93096-9&rft_dat=%3Cproquest_cross%3E81076269%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=81076269&rft_id=info:pmid/3117893&rft_els_id=S0163445387930969&rfr_iscdi=true |